SAN DIEGO, CA / ACCESS Newswire / January 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing ...
In a time when COAs are more nuanced, critical and complex than ever, researchers can turn to best practices to move forward ...
LYON, France--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial ...
“We are particularly gratified to reach concurrence with the FDA on the overall study design, endpoints, and patient populations,” said Aridis CEO Vu Truong. “This provides a clear clinical and ...
Izotropic announced today it has completed a comprehensive review of its R&D strategy to yield a differentiated offering for the Company's priority markets, while positioning the business for ...
"We are excited to see Pfizer advancing MesoC2 into clinical development rapidly, highlighting the potential of Nona's Harbour Mice® and integrated ADC platforms to deliver innovative cancer therapies ...
Traditional clinical trial data are pseudonymized data, and these data may not contain information on a patient that directly identifies them, like a name, address, or phone number. However, ...
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced ...
The "AI-based Clinical Trials Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The AI-based clinical trials market is driving a fundamental transformation in ...
LOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Company’s proposed single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback